Stockreport

Nuvation Bio and Eisai Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside U.S., China and Japan

Nuvation Bio Inc. Class A  (NUVB) 
PDF Strategic collaboration expands taletrectinib global reach with a leading oncology partnerEisai will receive exclusive development, registration and commercialization ri [Read more]